A study to assess the safety and tolerability of AZD1390 given with radiation therapy in patients with brain cancer

Study identifier:D6940C00002

ClinicalTrials.gov identifier:NCT03423628

EudraCT identifier:2017-002451-28

CTIS identifier:N/A

Recruiting

Official Title

A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination with Radiation Therapy in Patients with Glioblastoma Multiforme and Brain Metastases from Solid Tumors.

Medical condition

Recurrent Glioblastoma Multiforme

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD1390

Sex

All

Estimated Enrollment

120

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 02 Apr 2018
Estimated Primary Completion Date: 28 Feb 2025
Estimated Study Completion Date: 28 Feb 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria